Scholarlink

Purpose of Review <p>To summarize current evidence on the immediate and long-term safety profile of the available monoclonal biological therapy (MBT) approved for the treatment of severe asthma.</p> Recent Findings <p>Clinical trials and real-world studies have shown that MBT are generally well tolerated, although certain adverse effects such as local reactions, anaphylaxis, parasitic or viral infections, malignancy, and cerebrovascular events are of special concern in these therapies or have already been reported. The frequency and severity of these effects vary depending on the specific agent and patient characteristics.</p> Summary <p>MBT have significantly improved the management of severe asthma, yet continuous monitoring of their safety profile remains essential to optimize long-term outcomes and minimize risks.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Adverse Events of Biologics in Severe Asthma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月30日

查看全文
  • Jorge Sánchez,
  • Ana Caraballo,
  • Leidy Álvarez

摘要

Purpose of Review

To summarize current evidence on the immediate and long-term safety profile of the available monoclonal biological therapy (MBT) approved for the treatment of severe asthma.

Recent Findings

Clinical trials and real-world studies have shown that MBT are generally well tolerated, although certain adverse effects such as local reactions, anaphylaxis, parasitic or viral infections, malignancy, and cerebrovascular events are of special concern in these therapies or have already been reported. The frequency and severity of these effects vary depending on the specific agent and patient characteristics.

Summary

MBT have significantly improved the management of severe asthma, yet continuous monitoring of their safety profile remains essential to optimize long-term outcomes and minimize risks.